



# ISIC-2022 International Scientific Interdisciplinary Conference





<b>Bondarenko Kateryna</b> .....	<b>69</b>
STUDY OF CHANGES IN THE SKIN CONDITION OF STUDENTS AND ITS CARE DURING THE WAR.....	69
<b>Chorna Daria, Butenko Vlada</b> .....	<b>70</b>
FEATURES OF DRUG ALLERGY DIAGNOSTICS .....	70
<b>Chunikhovska Elina</b> .....	<b>72</b>
STATE OF PATIENTS WITH BRONCHIAL ASTHMA DURING WAR .....	72
<b>Dolyk Anastasia, Yakhno Yana</b> .....	<b>74</b>
PANIC ATTACKS AFTER EXPERIENCED COVID-19 AMONG MEDICAL STUDENTS .....	74
<b>Dvorechenets Danylo, Marchenko Iryna</b> .....	<b>76</b>
SELENIUM AND THE FUNCTIONING OF THE THYROID GLAND .....	76
<b>Fedorenko Olha</b> .....	<b>78</b>
GOUT AND A MODERN VIEW OF TREATMEN .....	78
<b>Habdrakhmanov Illia</b> .....	<b>79</b>
IRISIN, AS A DIAGNOSTIC MARKER OF THE DEVELOPMENT AND COURSE OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES AND OBESITY .....	79
<b>Katamadze Rusudan, Anyshchenko Anna</b> .....	<b>80</b>
TRANSFORMATION OF HELICOBACTER-ASSOCIATED CHRONIC GASTRITIS INTO ULCER DISEASE AND STOMACH CANCER .....	80
<b>Khudiakova Yulia, Horokhova Yelyzaveta</b> .....	<b>82</b>
EFFECTIVENESS OF TRIPLE FIXED ANTIHYPERTENSIVE THERAPY .....	82
<b>Kolomiets Sofiia, Bobro Lilia</b> .....	<b>84</b>
DIABETES MELLITUS IN UKRAINE DURING 2022 .....	84
<b>Kolomiets Sofiia, Zalubovska Olena</b> .....	<b>86</b>
ARTERIAL HYPERTENSION TREATMENT ALGORITHM .....	86
<b>Koshkina Marharyta, Fedorenko Olha</b> .....	<b>87</b>
TITIN AS A PREDICTOR OF THE COMORBID COURSE OF CORONARY ARTERY DISEASE AND TYPE 2 DIABETES MELITUS .....	87
<b>Koshurba Illia, Hladkykh Fedir</b> .....	<b>88</b>
PRECLINICAL STUDY OF GASTROPROTECTIVE ACTION OF CRYOPRESERVED PLACENTA EXTRACT .....	88
<b>Koteliukh Mariia, Dvorechenets Danylo, Marchenko Iryna</b> .....	<b>90</b>
IMMUNOLOGICAL ASPECTS OF ACUTE MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE 2 DIABETES AND OBESITY .....	90
<b>Kovalenko Anastasia, Bazylieva Yuliia, Orlova Maria</b> .....	<b>91</b>
EFFECTIVENESS OF THE COMBINATION OF ACE INHIBITORS AND INDAPAMIDE IN THE TREATMENT OF ARTERIAL HYPERTENSION .....	91
<b>Kukhar Iryna</b> .....	<b>93</b>
VALUE OF C-PEPTIDE MEASUREMENT IN BLOOD IN THE THERAPY OF PATIENTS WITH DIABETES MELLITUS .....	93
<b>Kuye Adesegun Jacobs, Azuwike Uchechi Blessing</b> .....	<b>94</b>
NEGATIVE IMPACT OF THE COVID-19 LOCKDOWN.....	94
<b>Minukhina Diana, Zeinab El Zein</b> .....	<b>96</b>
DYNAMIC'S FEATURES OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION WITH TYPE 2 DIABETES MELLITUS.....	96
<b>Ryasnyanski Timur</b> .....	<b>97</b>
MODERN MOST COMMON MANIFESTATIONS OF POST-WATER SYNDROME .....	97
<b>Satapathy Ayusha</b> .....	<b>98</b>
CLINICAL CASE OF ATYPICAL COURSE OF ULCERATIVE COLITIS .....	98
<b>Sypalo Anna, Tavby Khalyl</b> .....	<b>100</b>
ASSESSMENT OF THE QUALITY OF LIFE IN PATIENTS WITH CORONARY HEART DISEASE AND DIABETES MELLITUS TYPE 2 .....	100
<b>Ternopol Yuliia</b> .....	<b>101</b>
POSSIBILITIES OF RHINOCYTOGRAMS USING TO ASSES THE FUNCTIONAL STATE OF THE NOSE IN PATIENTS WITH LONG-TERM NASAL BREATHING DISORDER .....	101
<b>Tsymbal Iryna, Ivanchenko Svitlana</b> .....	<b>103</b>
ANALYSIS OF THE EFFICIENCY OF HYPOLIPIDEMICAL THERAPY IN PATIENTS WITH CARDIOVASCULAR DISEASES AND METABOLIC DISORDERS .....	103



*Koteliukh Mariia, Dvorechenets Danylo, Marchenko Iryna*  
**IMMUNOLOGICAL ASPECTS OF ACUTE MYOCARDIAL INFARCTION  
IN PATIENTS WITH TYPE 2 DIABETES AND OBESITY**

*Kharkiv National Medical University  
Department of Internal Medicine No. 2, Clinical Immunology and Allergology  
named after academician L.T. Malaya  
Kharkiv, Ukraine  
Scientific advisor: prof. Kravchun Pavlo Hryhorovych*

Introduction. Acute myocardial infarction (AMI) and obesity are common diseases among diabetic patients. The immunological mechanisms of the development of AMI in diabetic patients with excessive body weight is an insufficiently studied area and needs careful consideration.

The purpose of the study – to determine immunological markers of the development of AMI in patients with diabetes mellitus type 2 and obesity.

Methods. The study examined 31 patients with AMI, type 2 diabetes and obesity. The control group consisted of 20 practically healthy people. It was determined by the immunoenzymatic method adropin and Human Fatty acid Binding Protein 4 (FABP 4) with the use of a set of reagents «Human adropin», «FABP 4» (Elabscience Biotechnology, USA) and «C1q/TNF-related protein (CTRP 3)» (Aviscera Bioscience Inc, Santa Clara, USA) according to the indicated instructions for conducting the analysis. Statistical data processing was carried out with the help of a license package of programs “IBM SPSS Statistics 27.0”. The hypothesis about the normality of the distribution of indicators was carried out according to the Shapiro-Wilk test. Non-parametric methods were used according to the sample size and distribution of values. Interrelationships of indicators were analyzed using the correlation coefficient Spearman ( $r$ ). The difference was considered reliable at values of  $p < 0.05$ .

Results. It was determined that the level of adropin in patients with AMI, type 2 diabetes and obesity was reduced and amounted to 14.10 (8.23; 17.90) pg/ml compared to the control group of 23.58 (20.86; 26.29) pg /ml ( $p < 0.001$ ). The concentration of FABP 4 was increased in patients and amounted to 9.60 (8.73; 11.94) ng/ml compared to the control group - 4.25 (3.46; 6.16) ng/ml ( $p < 0.001$ ). The CTRP 3 content was reduced and was 193.44 (166.48, 250.11) ng/ml compared to the control group 315.85 (287.06, 371.02) ng/ml ( $p < 0.001$ ). In patients was found an inverse correlation between adropin and total cholesterol ( $r = -0.575$ ,  $p < 0.001$ ), low density lipoproteins



( $r = -0.485$ ,  $p = 0.006$ ), high density lipoproteins ( $r = -0.394$ ,  $p = 0.028$ ); between FABP 4 and total cholesterol ( $r = 0.363$ ,  $p=0.04$ ), triglycerides ( $r = 0.493$ ,  $p=0.006$ ); between CTRP 3 and triglycerides ( $r = -0.501$ ,  $p=0.005$ ), coefficient of atherogenicity ( $r = -0.366$ ,  $p = 0.04$ ).

Conclusion. It has been established that in patients with AMI, type 2 diabetes and obesity, there is a relationship between markers of energy, adipokine and lipid metabolism.

*Kovalenko Anastasia, Bazylieva Yuliia, Orlova Maria*  
**EFFECTIVENESS OF THE COMBINATION OF ACE INHIBITORS AND  
INDAPAMIDE IN THE TREATMENT OF ARTERIAL HYPERTENSION**

*Kharkiv National Medical University  
Department of Internal Medicine №1  
Kharkiv, Ukraine  
Scientific advisor: docent Galina Panchenko*

Topicality. Today, according to the recommendations of the European Society of Cardiologists for the diagnosis and treatment of heart failure (CH) (2021), ACE inhibitors (ACEI) are first-line drugs that should be taken on a permanent basis by patients with arterial hypertension (AH), coronary heart disease (CHD) and heart failure (HF). ACE inhibitors are recommended for all patients with hypertension, except for patients with intolerance or contraindications. First of all, this is due to the fact that ACE inhibitors perform a powerful hypotensive effect with pronounced organoprotective properties, namely, they are cardio-, nephro- and angioprotectors, which helps to reduce the frequency of complications and mortality.

It should be said that the most convincing evidence base is collected in the combination of ACE inhibitors with thiazide-like diuretics. When these groups of drugs interact, the hypotensive effect is enhanced. Diuretics dilate blood vessels by stimulating the synthesis of prostacyclin in the endothelium and prostaglandin E<sub>2</sub> in the kidneys, and inhibitors, in turn, block the mechanisms of blood pressure increase by blocking the synthesis of angiotensin II. One of the most popular combinations in cardiology is the combination of Perindopril and Indapamide.